Literature DB >> 6264937

The influence of age, smoking and hyperthyroidism on plasma propranolol steady state concentration.

J Feely, J Crooks, I H Stevenson.   

Abstract

1 Plasma propranolol steady state concentration (Css) was determined during chronic dosage (160 mg/day) in 22 hyperthyroid patients (aged 16-75 years, 11 smokers, 11 non-smokers) and again following treatment when euthyroid. 2 There was a positive correlation between plasma propranolol Css and age in patients both when hyperthyroid (r = 0.74, P less than 0.01) and when euthyroid (r = 0.58, P less than 0.05). 3 Plasma propranolol Css in hyperthyroid patients were lower (P less than 0.05) in smokers than in non-smokers. 4 Following correction of hyperthyroidism there was a significant increase (P less than 0.01) in both the plasma propranolol Css and degree of plasma protein binding of propranolol. 5 Hyperthyroidism and smoking are known to increase the rate of drug metabolism and it is suggested that these variables may give rise to or accentuate an age related reduction in propranolol clearance.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6264937      PMCID: PMC1401749          DOI: 10.1111/j.1365-2125.1981.tb01857.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  23 in total

1.  Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking.

Authors:  R E Vestal; A H Norris; J D Tobin; B H Cohen; N W Shock; R Andres
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Changes in drug metabolism with increasing age: 1. warfarin binding and plasma proteins.

Authors:  M J Hayes; M J Langman; A H Short
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

Review 3.  Individualization of propranolol therapy.

Authors:  D G Shand
Journal:  Med Clin North Am       Date:  1974-09       Impact factor: 5.456

4.  Adverse reactions to propranolol in hospitalized medical patients: a report from the Boston Collaborative Drug Surveillance Program.

Authors:  D J Greenblatt; J Koch-Weser
Journal:  Am Heart J       Date:  1973-10       Impact factor: 4.749

Review 5.  Adverse reactions to beta-adrenergic receptor blocking drugs: a report from the Boston collaborative drug surveillance program.

Authors:  D J Greenblatt; J Koch-Weser
Journal:  Drugs       Date:  1974       Impact factor: 9.546

6.  GLC determination of propranolol, other beta-blocking drugs, and metabolites in biological fluids and tissues.

Authors:  T Walle
Journal:  J Pharm Sci       Date:  1974-12       Impact factor: 3.534

7.  Changes in drug metabolism with increasing age: 2. phenytoin clearance and protein binding.

Authors:  M J Hayes; M J Langman; A H Short
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

8.  Effect of age, height, weight and sex on serum phenytoin concentration in epileptic patients.

Authors:  G W Houghton; A Richens; M Leighton
Journal:  Br J Clin Pharmacol       Date:  1975-06       Impact factor: 4.335

Review 9.  Drug metabolism in thyroid disease.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

Review 10.  Pharmacokinetics in the elderly.

Authors:  J Crooks; K O'Malley; I H Stevenson
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

View more
  9 in total

1.  A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls.

Authors:  R G Watson; W Bastain; K A Larkin; J R Hayes; J A McAinsh; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

2.  Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly.

Authors:  K W Woodhouse; H A Wynne
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

3.  Treating mild hypertension.

Authors:  A Breckenridge
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-13

Review 4.  Plasma protein binding of drugs in the elderly.

Authors:  S M Wallace; R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of beta-adrenoceptor blocking drugs in thyroid disease.

Authors:  J Feely
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

6.  Influence of age on serum protein binding of propranolol.

Authors:  R Bendayan; J A Pieper; R B Stewart; G J Caranasos
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.

Authors:  P O'Connor; J Feely
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

Review 8.  Use of beta-adrenoceptor blocking drugs in hyperthyroidism.

Authors:  J Feely; N Peden
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

9.  Paroxetine Attenuates Cardiac Hypertrophy Via Blocking GRK2 and ADRB1 Interaction in Hypertension.

Authors:  Xuejing Sun; Mengli Zhou; Gaiyan Wen; Yun Huang; Junru Wu; Liping Peng; Weihong Jiang; Hong Yuan; Yao Lu; Jingjing Cai
Journal:  J Am Heart Assoc       Date:  2020-12-29       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.